AMANDA WILLIS: Open Payments
NPI 1508559956 · ALTOONA, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$225 in 10 payments from 7 companies in 2025. Trend: 2023 $409 · 2024 $635 · 2025 $225
Food & beverage: $225
| Company | Payments | Amount |
|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $70 |
| Sumitomo Pharma America, Inc. | 2 | $47 |
| Atland Pharmaceuticals, LLC | 1 | $26 |
| Lilly USA, LLC | 1 | $22 |
| Novo Nordisk Inc | 1 | $21 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Amgen Inc. | 1 | $17 |
Products named: Kerendia, GEMTESA, ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE, MOUNJARO, Rybelsus, CAPLYTA, OTEZLA.
Industry payments across AL — which companies pay providers there.
